Target Name: GET4
NCBI ID: G51608
Review Report on GET4 Target / Biomarker Content of Review Report on GET4 Target / Biomarker
GET4
Other Name(s): Guided entry of tail-anchored proteins factor 4 | TRC35 | transmembrane domain recognition complex, 35kDa | Transmembrane domain recognition complex, 35kDa | Transmembrane domain recognition complex 35 kDa subunit | conserved edge protein | guided entry of tail-anchored proteins factor 4 | CGI-20 | Conserved edge protein | H_NH1244M04.5 | conserved edge expressed protein | Conserved edge expressed protein | C7orf20 | Conserved edge-expressed protein | GET4_HUMAN | Golgi to ER traffic protein 4 homolog | CEE | transmembrane domain recognition complex 35 kDa subunit | golgi to ER traffic protein 4

GET4: A Potential Drug Target or Biomarker for Tail-Anchored Proteins Factor 4

Proteins play a crucial role in various cellular processes, including but not limited to cell signaling, DNA replication, and response to stimuli. One of the well-known protein families is the Tail-Anchored Proteins (TAPs), which are involved in various cellular processes. TAPs are characterized by a unique mechanism of anchor via a protein called Tail, which interacts with the protein target and helps to keep it in a tailed state. Amino acids 1-92 of TAPs are usually involved in this process.

Recent studies have identified GET4, a protein that belongs to the TAP family, as a potential drug target or biomarker. GET4 is known to play a critical role in the regulation of cellular processes, including but not limited to cell signaling, apoptosis, and inflammation. In this article, we will discuss the potential implications of GET4 as a drug target or biomarker.

Potential Drug Target

Drugs that target specific proteins are becoming increasingly popular in modern medicine. GET4 is an attractive target due to its unique mechanism of action and its involvement in various cellular processes.

First, GET4 has been shown to play a role in cell signaling. GET4 is involved in the regulation of the PI3K/Akt signaling pathway, which is a well-established target for many diseases, including cancer. Activation of this pathway has been linked to various cellular processes, including cell growth, differentiation, and survival.

Second, GET4 is involved in the regulation of apoptosis, which is a natural cell death process that is essential for the development and progression of many diseases, including cancer. GET4 has been shown to play a role in the regulation of apoptosis by activating and inhibiting various cellular signaling pathways.

Third, GET4 is involved in the regulation of inflammation. Inflammation is a complex biological response to tissue damage, and it is a risk factor for many diseases, including cancer. GET4 has been shown to play a role in the regulation of inflammation by regulating various signaling pathways, including the production of pro-inflammatory cytokines.

Potential Biomarker

The identification of GET4 as a potential drug target or biomarker has significant implications for the development of new diagnostic tools and therapies. If GET4 is indeed a drug target, then inhibiting its activity could be a promising approach to treating various diseases. Additionally, if GET4 is a biomarker, then its levels or expression could be used as a diagnostic tool for certain diseases.

One of the potential applications of GET4 as a biomarker is its potential to serve as a therapeutic target for cancer. Cancer is a leading cause of death worldwide, and there is a significant need for new treatments. GET4 has been shown to play a role in the regulation of various cellular processes that are associated with cancer development, including the regulation of cell growth, apoptosis, and angiogenesis. Therefore, inhibiting GET4 activity could be a promising approach to treating cancer.

Another potential application of GET4 as a biomarker is its potential to serve as a diagnostic tool for certain diseases. The regulation of various cellular processes is a critical aspect of many diseases, including cancer. Therefore, measuring the levels or expression of GET4 could be a useful diagnostic tool for diseases associated with alterations in cellular processes.

Conclusion

In conclusion, GET4 is a protein that has been identified as a potential drug target or biomarker. Its unique mechanism of action and involvement in various cellular processes make it an attractive target for new therapies and diagnostic tools. Further research is needed to fully understand the role of GET4 in

Protein Name: Guided Entry Of Tail-anchored Proteins Factor 4

Functions: As part of a cytosolic protein quality control complex, the BAG6/BAT3 complex, maintains misfolded and hydrophobic patches-containing proteins in a soluble state and participates in their proper delivery to the endoplasmic reticulum or alternatively can promote their sorting to the proteasome where they undergo degradation (PubMed:20676083, PubMed:21636303, PubMed:21743475, PubMed:28104892). The BAG6/BAT3 complex is involved in the post-translational delivery of tail-anchored/type II transmembrane proteins to the endoplasmic reticulum membrane. Recruited to ribosomes, it interacts with the transmembrane region of newly synthesized tail-anchored proteins and together with SGTA and ASNA1 mediates their delivery to the endoplasmic reticulum (PubMed:20676083, PubMed:28104892, PubMed:25535373). Client proteins that cannot be properly delivered to the endoplasmic reticulum are ubiquitinated and sorted to the proteasome (PubMed:28104892). Similarly, the BAG6/BAT3 complex also functions as a sorting platform for proteins of the secretory pathway that are mislocalized to the cytosol either delivering them to the proteasome for degradation or to the endoplasmic reticulum (PubMed:21743475). The BAG6/BAT3 complex also plays a role in the endoplasmic reticulum-associated degradation (ERAD), a quality control mechanism that eliminates unwanted proteins of the endoplasmic reticulum through their retrotranslocation to the cytosol and their targeting to the proteasome. It maintains these retrotranslocated proteins in an unfolded yet soluble state condition in the cytosol to ensure their proper delivery to the proteasome (PubMed:21636303)

The "GET4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GET4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GFAP | GFER | GFI1 | GFI1B | GFM1 | GFM2 | GFOD1 | GFOD2 | GFPT1 | GFPT2 | GFRA1 | GFRA2 | GFRA3 | GFRA4 | GFRAL | GFUS | GGA1 | GGA2 | GGA3 | GGACT | GGCT | GGCX | GGH | GGN | GGNBP1 | GGNBP2 | GGPS1 | GGT1 | GGT2P | GGT3P | GGT5 | GGT6 | GGT7 | GGT8P | GGTA1 | GGTLC1 | GGTLC2 | GGTLC3 | GH1 | GH2 | GHDC | GHITM | GHR | GHRH | GHRHR | GHRL | GHRLOS | GHSR | GID4 | GID8 | GIGYF1 | GIGYF2 | GIHCG | GIMAP1 | GIMAP1-GIMAP5 | GIMAP2 | GIMAP3P | GIMAP4 | GIMAP5 | GIMAP6 | GIMAP7 | GIMAP8 | GIMD1 | GIN1 | GINM1 | GINS complex | GINS1 | GINS2 | GINS3 | GINS4 | GIP | GIPC1 | GIPC2 | GIPC3 | GIPR | GIT1 | GIT2 | GJA1 | GJA10 | GJA1P1 | GJA3 | GJA4 | GJA5 | GJA8 | GJA9 | GJA9-MYCBP | GJB1 | GJB2 | GJB3 | GJB4 | GJB5 | GJB6 | GJB7 | GJC1 | GJC2 | GJC3 | GJD2 | GJD3 | GJD4 | GK